Fields marked with an asterisk (
*) are required.
It is recommended that you read the RMA's
Submission guidelines before making your submission. Your details
Your address for correspondence
The condition under investigation or review accidental hypothermia accommodation disorder acoustic neuroma acquired cataract acute lymphoblastic leukaemia acute myeloid leukaemia adenocarcinoma of the kidney adrenal insufficiency alcohol use disorder Alzheimer-type dementia angle-closure glaucoma aortic stenosis atherosclerotic peripheral vascular disease Baker's cyst benign neoplasm of the eye and adnexa benign paroxysmal positional vertigo bipolar disorder bronchiolitis obliterans organising pneumonia cardiomyopathy carotid arterial disease cerebral meningioma cerebrovascular accident chemically-acquired brain injury caused by mefloquine, tafenoquine or primaquine chilblains chronic gastritis and chronic gastropathy chronic myeloid leukaemia chronic pancreatitis cirrhosis of the liver Cushing's syndrome electrical injury erectile dysfunction external burn femoro-acetabular impingement syndrome fibrosing interstitial lung disease frostbite gastric ulcer and duodenal ulcer goitre Graves' disease Guillain-Barre syndrome Hashimoto's thyroiditis heart block hepatitis C herpes simplex human immunodeficiency virus human T-cell lymphotropic virus type 1 hypopituitarism hypothyroidism immersion foot immune thrombocytopaenic purpura influenza ischaemic heart disease labral tear localised sclerosis macular degeneration malaria malignant neoplasm of bone and articular cartilage malignant neoplasm of the bile duct malignant neoplasm of the bladder malignant neoplasm of the brain malignant neoplasm of the breast malignant neoplasm of the cerebral meninges malignant neoplasm of the colorectum malignant neoplasm of the endometrium malignant neoplasm of the eye malignant neoplasm of the gallbladder malignant neoplasm of the liver malignant neoplasm of the lung malignant neoplasm of the oesophagus malignant neoplasm of the ovary malignant neoplasm of the renal pelvis and ureter malignant neoplasm of the salivary gland malignant neoplasm of the stomach malignant neoplasm of the thyroid gland malignant neoplasm of unknown primary site mesothelioma migraine motor neurone disease multiple sclerosis myelodysplastic syndrome myeloma narcolepsy neoplasm of the pituitary gland non-aneurysmal aortic atherosclerotic disease non-Hodgkin's lymphoma non-melanotic malignant neoplasm of the skin open-angle glaucoma optochiasmatic arachnoiditis osteoarthritis osteomyelitis otitis externa otitis media panic disorder peritoneal adhesions personality disorder popliteal entrapment syndrome renal artery atherosclerotic disease rheumatoid arthritis scrub typhus sickle-cell disorder sinusitis soft tissue sarcoma substance use disorder systemic sclerosis tension-type headache the definition of the term 'cumulative equivalent dose' used in the 'ionising radiation factor' tinnitus tooth wear toxic maculopathy trigeminal neuropathy ulnar nerve entrapment at the elbow Zika virus infection Submission
In the space provided below, please detail the submission you consider to make for the RMA's consideration. If you have prepared a submission in a digital form able to be uploaded (.doc or .pdf), you have the option of including it as an attachment below.
Attach any documents relevant to your submission using the fields below (.doc or .pdf).
Disclosure of information
Under section 196K of the VEA, certain decisions made by the Authority are reviewable by the Specialist Medical Review Council (SMRC). If a valid application for review by the SMRC is made, the VEA requires the Authority to disclose to the SMRC all information relevant to its determination or decision. This includes applications for investigation or review, and submissions received relevant to the matter being review by the SMRC.
I have read and understood the above disclosure of information statement.
I have read the
RMA Submission Guidelines and understand what is 'sound medical-scientific evidence' (SMSE) which can be used by the RMA to make or amend a SOP.
Once you have completed your submission, the information will be available in a PDF format for you to save (or print out) for your records.